Amgen Buys Rights From Human Genome
- Share via
From Bloomberg News
Amgen Inc. of Thousand Oaks acquired rights from Human Genome Sciences Inc. to develop and sell potential treatments for cancer and immune deficiencies.
A statement by Human Genome didn’t disclose the price. The potential treatments and tests are based on a gene identified by the company.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
